Samsung Biologics to construct manufacturing plant for next-gen vaccines, C>s
CDMO's new South Korean facility to offer a range of production services
Samsung Biologics, a contract development and manufacturing organization (CDMO), plans to start building a new facility (designated Plant 5) at Songdo in Incheon, South Korea, this year. The plant will offer manufacturing for multi-modal products, including cell and gene therapies (C>s) and next-generation vaccines that utilize mRNA, plasmid DNA, and viral vectors. The expansion is part of the company’s 2022 growth plan.
The facility will be an addition to the mRNA vaccine drug substance (DS) manufacturing suite that the company is currently adding to its existing facility in Songdo. The mRNA vaccine DS facility is expected to be ready for current good manufacturing practice (GMP) operations within the earlier part of this year, notes the CDMO.
Samsung Biologics is also looking to secure additional sites within Songdo for the future construction of another additional facility (designated Plant 6) and an open innovation center. In addition, the company is looking for overseas sites in multiple locations to maximize both its manufacturing capacity for producing large-scale biologics and to be in close proximity to global clients.
The company's Plant 4 is currently under construction and is expected to be partially operational by the end of this year. When Plant 4 is fully completed in 2023, it is anticipated have a total capacity of 620,000 L.
“Through proactive investment in increasing our manufacturing capacity, enhancing portfolio diversification, and expanding facilities in overseas, Samsung Biologics will be able to accelerate the build-up of its core success drivers as the next growth engine of the industry,” says John Rim, CEO of Samsung Biologics.
